Synergy Pharmaceuticals to Present at Bank of America Merrill Lynch Health Care Conference

NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals, Inc. (OTC QB:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced that Dr. Gary S. Jacob, President and Chief Executive Officer, is scheduled to present at the Bank of America Merrill Lynch 2011 Health Care Conference on Wednesday, May 11, 2011 at 3:00 pm Pacific Time at the Encore at Wynn Hotel in Las Vegas, NV.

The live webcast can also be accessed under the "Investor Relations" tab on the company's website at www.synergypharma.com. The webcast will be archived for 90 days.

About Synergy Pharmaceuticals, Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal hormone uroguanylin, and functions by activating the guanylate cyclase C (GC-C) receptor on epithelial cells of the GI tract. Plecanatide has recently completed a Phase IIa clinical trial in patients to treat CC. The Company plans to initiate a Phase II/III 90-day repeated-oral-dose, placebo-controlled clinical trial of plecanatide in CC patients in the second half of 2011. Plecanatide is also being developed to treat IBS-C, with the first trial in IBS-C patients planned for 2012. More information is available at http://www.synergypharma.com.



CONTACT:

Synergy Pharmaceuticals, Inc.
Gary S. Jacob, Ph.D., 212-297-0020
President and CEO
[email protected]
or
Investor and Media:
Rx Communications Group, LLC
Melody A. Carey, 917-322-2571
[email protected]

KEYWORDS:   United States  North America  Nevada  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical

MEDIA:

Suggested Articles

Panelists at the CAR-TCR Summit reflected on gender diversity trends and the challenges women face in the life sciences industry.

Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.

The $3 billion funding boost includes an additional $350 million for targeted Alzheimer’s research.